Comparing Vaxcyte (NASDAQ:PCVX) & Immunovant (NASDAQ:IMVT)

Immunovant (NASDAQ:IMVT) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Immunovant and Vaxcyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-63.17%	-58.01%
Vaxcyte	N/A	-21.08%	-19.67%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Immunovant and Vaxcyte, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1	3	6	1	2.64
Vaxcyte	1	1	7	1	2.80

Immunovant presently has a consensus price target of $31.11, indicating a potential upside of 20.82%. Vaxcyte has a consensus price target of $93.83, indicating a potential upside of 73.44%. Given Vaxcyte’s stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Immunovant.

Risk & Volatility

Immunovant has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Immunovant and Vaxcyte”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$413.84 million	($2.69)	-9.57
Vaxcyte	N/A	N/A	-$463.93 million	($4.84)	-11.18

Vaxcyte is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Summary

Vaxcyte beats Immunovant on 8 of the 11 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About Vaxcyte

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.